---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-082358"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2022-12-23T23:59:59+00:00"
generated_at: "2026-06-20T23:40:57.424898+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Allarity gets Nasdaq extension to April 10, 2023 to meet $2.5M equity requirement

## Summary
- Nasdaq granted extension until April 10, 2023, to regain compliance with $10M equity rule.
- Company plan includes raising capital and moving to Nasdaq Capital Market ($2.5M equity).
- Previous notice of deficiency received October 12, 2022; plan submitted December 12, 2022.
- No assurance given that compliance will be achieved by the extended deadline.

## SEC filing metadata
- accession: 0001213900-22-082358
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2022-12-23T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390022082358/0001213900-22-082358-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390022082358/ea170792-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-082358
- JSON: https://secwatch.observer/filing/0001213900-22-082358.json
- Plain text: https://secwatch.observer/filing/0001213900-22-082358.txt

## Key facts
- Listing & Compliance Notices
  Allarity Therapeutics, Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5450(b)(1)(A)).
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: stockholders equity
  - Rules: 5450(b)(1)(A)
  source text: December 21, 2022, the Company received notification from the Nasdaq staff that they have granted the Company an extension of time until April 10, 2023, to regain and evidence compliance with the Rule. No assurance can be given that the Company will be able to regain compliance with the Rule by April 10, 2023, as well as meet other notifications of deficiency subject to previous disclosure on Form 8-K (See Form 8-Ks filed with the SEC on November 25, and December 20, 2022). 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this rep
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390022082358/0001213900-22-082358-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.